29 Result(s)
within
Gareth J. Morgan
English
Oncology
-
Article
Open AccessAnthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features
Obesity is an established modifiable risk factor for multiple myeloma (MM). However, associations of obesity and MM risk in Black populations, for whom obesity and MM are more common, is less clear.
-
Article
Computed tomographic parenchymal lung findings in premature infants with pulmonary vein stenosis
Developmental pulmonary vein pulmonary vein stenosis in the setting of prematurity is a rare and poorly understood condition. Diagnosis can be challenging in the setting of chronic lung disease of prematurity....
-
Article
Open AccessA pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Some cytogenetic abnormalities (CAs) are associated with poorer prognosis in multiple myeloma (MM); proteasome inhibitors appear to benefit patients with high-risk CAs. We evaluated 2247 MM patients from the T...
-
Article
Open AccessStructural variants shape the genomic landscape and clinical outcome of multiple myeloma
Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show th...
-
Article
Open AccessIxazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, con...
-
Article
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-described. Despite not being a diagnostic criterion, infection is a common complication of most PCD and represents a ...
-
Article
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups
Sequencing studies have shed some light on the pathogenesis of progression from smouldering multiple myeloma (SMM) and symptomatic multiple myeloma (MM). Given the scarcity of smouldering samples, little data ...
-
Article
Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length
-
Article
Open AccessInsights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
Despite improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused a...
-
Article
Open AccessCopy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. ...
-
Article
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy....
-
Article
Open AccessPredicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
-
Article
Open AccessInternational Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitatin...
-
Article
Open AccessAn enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
Most patients with multiple myeloma (MM) die from progressive disease after relapse. To advance our understanding of MM evolution mechanisms, we performed whole-genome sequencing of 80 IGH-translocated tumour-nor...
-
Article
Open AccessThe functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
Multiple Myeloma (MM) is a hematological malignancy with genomic heterogeneity and poor survival outcome. Apart from the central role of genetic lesions, epigenetic anomalies have been identified as drivers in...
-
Article
Open AccessAn acquired high-risk chromosome instability phenotype in multiple myeloma: Jum** 1q Syndrome
Patients with multiple myeloma (MM) accumulate adverse copy number aberrations (CNAs), gains of 1q21, and 17p deletions during disease progression. A subset of these patients develops heightened 1q12 pericentr...
-
Article
Open AccessSubclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
Multiple myeloma (MM) is a largely incurable haematological malignancy defined by the clonal proliferation of malignant plasma cells (PCs) within the bone marrow. Clonal heterogeneity has recently been establi...
-
Article
Open AccessGenetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multip...
-
Article
Open AccessKinase domain activation through gene rearrangement in multiple myeloma
Chromosomal rearrangements that result in oncogenic kinase activation are present in many solid and hematological malignancies, but none have been reported in multiple myeloma (MM). Here we analyzed 1421 sampl...
-
Article
Open AccessMAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
Multiple myeloma (MM) patients with t(14;20) have a poor prognosis and their outcome has not improved following the introduction of bortezomib (Bzb). The mechanism underlying the resistance to proteasome inhib...
